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Abstract Using NIH 3T3 cells, we have investigated nuclear
phosphoinositide metabolism in response to insulin, a molecule
which acts as a proliferating factor for this cell line and which is
known as a powerful activator of the mitogen-activated protein
(MAP) kinase pathway. Insulin stimulated inositol lipid meta-
bolism in the nucleus, as demonstrated by measurement of the
diacylglycerol mass produced in vivo and by in vitro nuclear
phosphoinositide-specific phospholipase C (PI-PLC) activity
assay. Despite the fact that nuclei of NIH 3T3 cells contained
all of the four isozymes of the L family of PI-PLC (i.e. L1, L2,
L3, and L4), insulin only activated the L1 isoform. Insulin also
induced nuclear translocation of MAP kinase, as demonstrated
by Western blotting analysis, enzyme activity assays, and
immunofluorescence staining, and this translocation was blocked
by the specific MAP kinase kinase inhibitor PD98059. By means
of both a monoclonal antibody recognizing phosphoserine and in
vivo labeling with [32P]orthophosphate, we ascertained that
nuclear PI-PLC-L1 (and in particular the b subtype) was
phosphorylated on serine residues in response to insulin. Both
phosphorylation and activation of nuclear PI-PLC-L1 were
substantially reduced by PD98059. Our results conclusively
demonstrate that activation of nuclear PI-PLC-L1 strictly
depends on its phosphorylation which is mediated through the
MAP kinase pathway. ß 2000 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Previous work from several independent laboratories has
established the presence of a nuclear inositol lipid metabolism
which is involved in the control of cell proliferation and di¡er-
entiation [1^3]. The evidence supporting the existence within
the nucleus of a polyphosphoinositide cycle derives from the
use of di¡erent methodologies, ranging from enzymatic activ-
ity measurements in various nuclear subfractions to immuno-
electron microscopy and, more recently, to molecular biology
techniques (e.g. [4^8]). One of the most intriguing aspects of
the nuclear polyphosphoinositide metabolism is that it is
clearly distinct from the classic inositol lipid cycle located at
the plasma membrane level. Therefore, there are in the liter-
ature numerous examples of stimuli that selectively activate
the nuclear cycle only (e.g. [2]).
In the nuclear inositol lipid cycle a pivotal role is played by
phosphoinositide-speci¢c phospholipase C (PI-PLC) L1, the
enzyme that hydrolyzes phosphatidylinositol 4,5-bisphosphate
(PtdIns(4,5)P2) yielding the two second messengers, diacylgly-
cerol (DAG) and inositol 1,4,5-trisphosphate (Ins(1,4,5)P3).
Nuclear PI-PLC-L1 is activated in response to di¡erent stimuli
such as insulin-like growth factor-I (IGF-I) and interleukin 1K
[9,10]. In IGF-I-treated Swiss 3T3 cells this activation resulted
in increased intranuclear levels of DAG which are essential
for attracting to this organelle the K isoform of protein kinase
C [11]. Very recent data coming from our laboratory have
highlighted the fact that nuclear PI-PLC-L1 controls cell cycle
progression conceivably through mechanisms involving cyclin
D3 and its kinase cdk4 [12]. Despite the fact that intranuclear
phosphoinositide metabolism was ¢rst described 13 years ago
[13], our knowledge of the mechanisms which control it is
extremely limited. As a ¢rst step in elucidating how nuclear
PI-PLC-L1 activity could be regulated, we have recently dem-
onstrated that, in Swiss 3T3 ¢broblasts, IGF-I-elicited activa-
tion of PI-PLC-L1 is dependent on a phosphorylation of the
phospholipase, possibly mediated by mitogen-activated pro-
tein (MAP) kinase [14].
It should be remembered that members of the L family of
PI-PLC (L1, L2, L3, and L4) possess a unique COOH-terminal
domain downstream of their catalytic domain. This domain is
highly enriched in lysine and arginine residues, which are con-
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served in all the four members of the L family. These basic
residues are very important in determining the nuclear local-
ization of PI-PLC-L1 [15]. Consistently with their molecular
structure, also the L2, L3, and L4 isoforms are present in the
nucleus of NIH 3T3 ¢broblasts [16]. NIH 3T3 cells represent
an interesting model to study the pathways which lead to cell
proliferation. Some clones of NIH 3T3 cells respond to insulin
alone [17]. Insulin is known to induce an intranuclear migra-
tion of MAP kinase (e.g. [18]). Therefore, it could be consid-
ered to be an activator of nuclear PI-PLC-L1.
In this paper, we have investigated whether or not changes
in nuclear polyphosphoinositide metabolism took place in
NIH 3T3 cells stimulated with insulin, and we have sought
to determine if PI-PLC L family isozymes other than L1 could
be activated at the nuclear level by the growth factor. More-
over, we have ascertained whether MAP kinase could be in-
volved in the regulation of the nuclear inositol lipid cycle in
response to insulin.
2. Materials and methods
2.1. Materials
ET-18-OCH3, PD98059, and protein G plus/protein A agarose
were from Calbiochem (La Jolla, CA, USA). The p42/p44 MAP
kinase enzyme assay system, [3H]PtdIns(4,5)P2, [32P]orthophosphate,
[Q-32P]ATP, £uorescein isothiocyanate (FITC)-conjugated anti-mouse
IgG, peroxidase-conjugated anti-rabbit, anti-mouse IgG, and anti-
mouse IgM, and the enhanced chemiluminescence (ECL) detection
kit were from Amersham Pharmacia Biotech (Uppsala, Sweden).
The protein assay kit (detergent-compatible) was from Bio-Rad (Her-
cules, CA, USA). Monoclonal antibody to 5P-bromodeoxyuridine (5P-
BrdU) was from Becton Dickinson (Palo Alto, CA, USA). A⁄nity-
puri¢ed rabbit polyclonal antibodies to all PI-PLC isoforms except L1
were obtained from Santa Cruz Biotechnology, Santa Cruz, CA,
USA. Also from Santa Cruz was a rabbit polyclonal antibody to
MAP kinase. A monoclonal antibody recognizing the N-terminus of
PI-PLC-L1 was obtained from Transduction Laboratories, Lexington,
KY, USA. Monoclonal antibody to phosphoserine (clone 16B4, an
IgM) was purchased form Alexis Biochemicals, Laufel¢ngen, Switzer-
land. Monoclonal antibody recognizing the phosphorylated (Thr202/
Tyr204) form of p42/44 MAP kinase was from New England BioLabs
Inc., Beverly, MA, USA. Insulin, epidermal growth factor (EGF), and
basic ¢broblast growth factor (bFGF) were obtained from Roche
Molecular Biochemicals, Milan, Italy. Monoclonal antibody to L-tu-
bulin and all of the other reagents of highest purity grade were from
Sigma Chemical Co. (St. Louis, MO, USA).
2.2. Cell culture
NIH 3T3 ¢broblasts (ATCC CRL 1658) were cultured in Dulbec-
co’s minimum essential medium (D-MEM) containing 10% fetal calf
serum. Prior to stimulation, cells were subcultured at a density of 104/
cm2, and incubated until they became con£uent (6 days). They were
then cultured for an additional 24 h in serum-free medium containing
0.5% bovine serum albumin (BSA). Quiescent cultures were washed
twice with serum-free medium containing 0.2% BSA, then incubated
in the same medium for the indicated times in the presence of insulin
(1 Wg/ml), bFGF (2 ng/ml), or EGF (10 ng/ml). The ET-18-OCH3 PI-
PLC inhibitor (100 WM) was present starting 5 min prior to stimula-
tion with insulin. For experiments performed in the presence of
PD98059, the compound was present at 20 WM for 1 h prior to
stimulation.
2.3. Cell cycle analysis
This was accomplished as reported elsewhere [6]. Brie£y, cells were
labeled for 60 min with 100 WM 5P-BrdU, ¢xed in ice-cold 70% etha-
nol, incubated for 30 min in 4 N HCl, and then reacted with a FITC-
conjugated monoclonal antibody to 5P-BrdU for 30 min at 4‡C, fol-
lowed by propidium iodide (5 Wg/ml) counterstaining. Samples were
analyzed by means of a FACStar Plus £ow cytometer (Becton Dick-
inson, Palo Alto, CA, USA).
2.4. Preparation of isolated nuclei and of cytoplasmic fraction
The preparation of nuclei stripped of their envelopes was accom-
plished as previously reported [9,14,16]. Brie£y, cells (5U106) were
suspended in 500 Wl of 10 mM Tris^HCl, pH 7.8, 1% Nonidet P-40,
10 mM L-mercaptoethanol, 0.5 mM phenylmethylsulfonyl £uoride,
1 Wg/ml of leupeptin and aprotinin for 2 min at 0‡C. Then 500 Wl
of double-distilled H2O was added and the cells allowed to swell for
2 min. Cells were sheared by 10 passages through a 22-gauge needle.
Nuclei were recovered by centrifugation at 400Ug for 6 min and
washed once in 10 mM Tris^HCl, pH 7.4, 2 mM MgCl2, plus protease
inhibitors as above. Preparation of nuclei retaining the envelopes was
performed in the absence of Nonidet P-40, by leaving the cells to swell
after the addition of double-distilled H2O for 5 min [16]. To obtain
the cytoplasmic fraction, cells were resuspended in 10 mM Tris^HCl,
pH 7.8, 2 mM MgCl2 and protease inhibitors as for nuclei, then ho-
mogenized with 20 strokes in a Dounce homogenizer. Nuclei were
sedimented at 400Ug for 6 min.
2.5. Electron microscopy
Pelleted NIH 3T3 cell nuclei obtained with the two di¡erent meth-
ods reported above were processed for transmission electron micro-
scope analysis. Brie£y, they were ¢xed with 2.5% glutaraldehyde in
0.1 M phosphate bu¡er for 35 min, post¢xed in 1% osmium tetroxide
and embedded in Araldite. Thin sections were stained with uranyl
acetate and lead citrate and observed with a Philips CM10 electron
microscope.
2.6. Measurement of DAG mass produced in vivo, PI-PLC and MAP
kinase activity assays
The DAG levels were measured according to Divecha et al. [4],
using DAG kinase enzyme puri¢ed from rat brain. For the PI-PLC
activity assay, the procedure outlined by Martelli et al. [9] was fol-
lowed. MAP kinase activity was analyzed by using the Biotrak MAP
kinase assay according to the manufacturer’s instructions.
2.7. Solubilization of nuclear PI-PLC isoforms and
immunoprecipitation
Membrane-deprived nuclei were resuspended at 1 mg DNA/ml in
5 mM Tris^HCl, pH 8.0, 0.1 mM EDTA and allowed to swell at 4‡C
for 10 min before rupturing by 40 passages through a 25-gauge hypo-
dermic needle. The lysate was centrifuged for 10 min at 48 000Ug. 5 Wg
of protein from nuclear lysates was incubated under constant agita-
tion for 1 h at 4‡C in the presence of 1.25 Wg of antibody to the
various PI-PLC-L isoforms. Protein G plus/protein A agarose was
then added to 10% (w/v) and incubation proceeded for an additional
60 min. Immune complexes were collected by centrifugation, and the
supernatant was assayed for residual PI-PLC activity [10].
2.8. Western blotting analysis
80 Wg of nuclear or cytoplasmic protein, separated on 7.0% SDS^
PAGE, was transferred to nitrocellulose sheets using a semi-dry blot-
ting apparatus. Sheets were saturated in phosphate-bu¡ered saline,
pH 7.4 (PBS), containing 5% normal goat serum and 4% BSA for
1 h at 37‡C (blocking bu¡er), then incubated overnight at 4‡C in
blocking bu¡er containing primary antibodies. After four washes in
PBS containing 0.1% Tween-20, samples were incubated for 30 min at
room temperature with peroxidase-conjugated secondary antibodies,
diluted 1:5000 in PBS^Tween-20, and washed as above. Bands were
visualized by the ECL method. When required, densitometric analysis
was performed on the Molecular Analyst GS670 (Bio-Rad).
2.9. In vivo labeling with [32P]orthophosphate
Cells were labeled for 6 h in phosphate-free D-MEM in the pres-
ence of 200 WCi/ml [32P]orthophosphate. Nuclei (from 2U107 cells)
were then isolated from control and insulin-treated cells in bu¡ers
containing 2.0 mM Na3VO4 and 5 mM NaF, lysed and immunopre-
cipitation was carried out with anti-PLC-L1 antibodies, as detailed
above. Samples were then electrophoresed, blotted, and autoradio-
graphed.
2.10. Immuno£uorescence staining
Cells growing on coverslips were ¢xed with freshly made 4% para-
formaldehyde in PBS for 30 min at room temperature, permeabilized
with 0.2% Triton X-100 for 10 min, then incubated for 3 h at 37‡C
with a monoclonal antibody (diluted 1:30) recognizing activated
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(phosphorylated) MAP kinase. The secondary antibody was a FITC-
conjugated anti-mouse IgG, diluted 1:200. Samples were photo-
graphed using a Zeiss Axiophot epi£uorescence microscope.
3. Results
3.1. Cell proliferation
The e¡ects of insulin, bFGF, and EGF on cell proliferation
were studied by £ow cytometry of 5P-BrdU-labeled cells. All
of these growth factors are known to activate MAP kinase
[8,19,20]. As shown in Fig. 1, insulin (1 Wg/ml) induced DNA
replication in approximately 18 þ 2% of the cells. In contrast,
neither bFGF nor EGF had any signi¢cant e¡ect on cell pro-
liferation. Because of these results, we decided to restrict any
further analysis to insulin-stimulated cells alone.
3.2. Purity of nuclear fractions
As shown in Fig. 2A, nuclei obtained without detergent
retained the nuclear envelope, whereas if Nonidet P-40 was
present during the preparations, the envelope was completely
stripped (Fig. 2B). As demonstrated by Western blotting anal-
ysis (Fig. 2C), nuclei retaining the envelope were contami-
nated by L-tubulin, which, on the other hand, was completely
absent from preparations of membrane-free nuclei.
3.3. DAG mass levels and PI-PLC activity in subcellular
fractions
We ¢rst measured in vivo DAG mass levels following stim-
ulation with insulin. As shown in Table 1, a 2 min incubation
with insulin caused a 32% rise in DAG mass in membrane-
stripped nuclei only. At 60 min of stimulation this value had
almost completely returned to basal levels. We next assayed
PI-PLC activity in samples treated with insulin. As presented
in Table 1, stimulation of quiescent NIH 3T3 cells for 2 or 60
min did not signi¢cantly a¡ect PI-PLC activity in either cyto-
plasmic fraction or nuclei retaining their envelope. In con-
trast, in preparations of envelope-stripped nuclei, PI-PLC ac-
tivity rose about two-fold over basal levels (from 10.5 þ 2.1 to
21.47 þ 3.1 nmol Ins(1,4,5)P3/mg protein/30 min of incuba-
tion) at 2 min of stimulation, while at 60 min it was reduced
to 12.5 þ 2.9 nmol Ins(1,4,5)P3/mg protein/30 min of incuba-
tion. Pretreatment of cells with a pharmacological inhibitor of
PI-PLC (ET-18-OCH3, employed at 100 WM) almost com-
pletely abolished the activity in all the subcellular fractions
prepared from either quiescent or growth factor-stimulated
cells.
Fig. 1. E¡ect of insulin, bFGF, and EGF on the proliferation of
NIH 3T3 cells. 20 h after exposure to the growth factors cells were
incubated for 60 min with 100 WM 5P-BrdU, labeled with an anti-
5P-BrdU antibody, and then analyzed by £ow cytometry. The histo-
grams show the percentage of labeled nuclei. The data represent the
mean from three di¡erent experiments þ S.D.
Fig. 2. A,B: Electron microscopy pictures of nuclei isolated from
NIH 3T3 cells by means of two di¡erent techniques. A: Nuclei iso-
lated in the absence of 1% Nonidet P-40 still retain the envelope. B:
Nuclei isolated in the presence of the detergent are completely
stripped of the envelope. C: Western blotting analysis with mono-
clonal antibody to L-tubulin. Lane 1: cytoplasmic fraction; lane 2:
intact nuclei; lane 3: membrane-deprived nuclei. Bands with a Mr
of 55 kDa were detected.
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3.4. PI-PLC isoforms present in subcellular fractions of NIH
3T3 cells
Recent results from our laboratory [16] have demonstrated
the existence, in the nucleus of NIH 3T3 cells, of all the
members of the L family of PI-PLC: L1, L2, L3, and L4. In
Fig. 3 we con¢rm these data by Western blotting analysis.
However, since for these experiments we employed a mono-
clonal antibody to the N-terminus of PI-PLC-L1, we were able
to detect that in membrane-stripped nuclei the b subtype of
this isoform is more represented, while in both membrane-
retaining nuclei and cytoplasm the a subtype of PI-PLC-L1
predominates. In addition, we show that PLC-Q1 was also
present in the cytoplasmic fraction and in preparations of
Table 1
In vivo DAG mass levels and in vitro PI-PLC activity in NIH 3T3 cell subcellular fractions after stimulation with 1 Wg/ml insulin














Control 313.6 þ 27.7 187.0 þ 15.7 99.1 þ 7.7 114.6 þ 18.1 20.4 þ 3.1 10.5 þ 2.1
Insulin 2 min 321.1 þ 27.3 195.8 þ 21.2 131.8 þ 15* 122.9 þ 23.4 23.6 þ 3.7 21.5 þ 3.1*
Insulin 60 min 329.8 þ 34.9 199.3 þ 18.0 106.6 þ 12.3 119.7 þ 20.4 21.6 þ 3.8 12.5 þ 2.9
Control, plus ET-18-OCH3 ND ND ND 9.3 þ 1.5 2.9 þ 0.8 1.6 þ 0.9
Insulin 2 min, plus ET-18-
OCH3
ND ND ND 10.1 þ 1.7 2.7 þ 0.6 1.8 þ 1.1
The data represent the mean from three di¡erent experiments þ S.D. The asterisks indicate signi¢cant di¡erences (P6 0.01) in a Student’s
paired t-test. ND, not determined.
Fig. 3. Western blotting analysis of PI-PLC isozymes in subcellular fractions of NIH 3T3 cells. Lane 1: envelope-stripped nuclei. Lane 2: nuclei
retaining the envelope. Lane 3: cytoplasmic fraction. 80 Wg of protein was blotted to each lane.
FEBS 24406 11-12-00
A.M. Martelli et al./FEBS Letters 486 (2000) 230^236 233
nuclei retaining the envelope, but not in membrane-stripped
nuclei. In contrast, PLC-N1 was not expressed at all in these
cells.
3.5. Insulin selectively stimulates nuclear PI-PLC-L1 activity
Since membrane-stripped nuclei retain all of the four mem-
bers of the L family of PI-PLC, it was very important to
determine which (if any) of these isoforms was activated in
response to insulin. To this end, nuclei were lysed and the
lysates were subjected to immunoprecipitation with antibodies
speci¢c for the various PI-PLC-L isozymes. Then, residual PI-
PLC activity was assayed in the supernatant of the immuno-
precipitates. As shown in Fig. 4, only the antibody to PI-PLC-
L1 was capable of reducing in a signi¢cant manner PI-PLC
activity which remained in the supernatant of the lysates after
immunoprecipitation, both in control nuclei (from 9.8 þ 2.0 to
4.7 þ 0.8 nmol Ins(1,4,5)P3/mg protein/30 min of incubation)
and in nuclei prepared from growth factor-stimulated cells
(from 21.2 þ 3.4 to 7.4 þ 1.8 nmol Ins(1,4,5)P3/mg protein/30
min of incubation).
3.6. Insulin induces translocation to the nucleus of MAP kinase
and serine phosphorylation of nuclear PI-PLC-L1
Since our previous results suggested (but did not prove)
that phosphorylation of nuclear PI-PLC-L1 was dependent
on MAP kinase [14], we decided to verify this issue in NIH
3T3 cells. As shown in Fig. 5A, some nuclear immunoreactiv-
ity for MAP kinase (both the p42 and the p44 isoform) was
detected in control nuclei. Insulin was capable of inducing a
marked nuclear translocation of MAP kinase already after
1 min of stimulation. The amount of intranuclear MAP kinase
further increased at 2 min after the beginning of stimulation
with the growth factor. In vitro assays also revealed a marked
increase in intranuclear activity of MAP kinase already after
1 min of stimulation with insulin (Fig. 5B). Furthermore, im-
muno£uorescence staining of insulin-stimulated NIH 3T3 cells
with a monoclonal antibody which speci¢cally reacts with
activated (phosphorylated) MAP kinase showed the enzyme
to be present within the nucleus after 1 min of treatment with
the growth factor (Fig. 5C).
The overall amount of intranuclear PI-PLC-L1 recovered
by immunoprecipitation (both the a and b subtypes) did not
change in response to insulin, nor it was a¡ected by incuba-
tion with PD98059, a selective pharmacological inhibitor of
MAP kinase kinase (MEK) (Fig. 6A). The blots from the
immunoprecipitates shown in Fig. 6A were then stripped
and reprobed with an antibody to phosphoserine. As pre-
sented in Fig. 6B, anti-phosphoserine antibody barely stained
the immunoprecipitates from control cells. In response to a
2 min stimulation with insulin, we detected a marked increase
in the immunoreactivity, especially regarding the b subtype of
PI-PLC-L1. The increase was reduced if the cells had been
incubated for 1 h with PD98059 prior to insulin stimulation.
Indeed, in this case, the densitometric analysis revealed a 63%
decrease in the intensity of the immunoreactive bands.
Fig. 4. Residual soluble nuclear PI-PLC activity following immuno-
precipitation with antibodies to the di¡erent isozymes of the L fam-
ily. Data are expressed as mean from three di¡erent experiments
þ S.D.
Fig. 5. Insulin (Ins) induces translocation to the nucleus of MAP ki-
nase. A: Western blotting analysis with a polyclonal antibody show-
ing intranuclear translocation of MAP kinase. B: Histograms show-
ing enhanced nuclear MAP kinase activity in response to insulin.
C: Immuno£uorescence staining of NIH 3T3 cells (control and insu-
lin-treated) using a monoclonal antibody to phosphorylated MAP
kinase. In B, results represent the mean þ S.D. of triplicate determi-
nations.
FEBS 24406 11-12-00
A.M. Martelli et al./FEBS Letters 486 (2000) 230^236234
When nuclei prepared from in vivo [32P]orthophosphate-
labeled cells were lysed and immunoprecipitated using an anti-
body speci¢c to the PI-PLC-L1 b splicing variant [21], it was
possible to see a dramatic increase in the phosphorylation of
the phospholipase in response to a 2 min stimulation with
insulin. This increase was almost completely prevented by
pretreatment of cells with PD98059 (Fig. 6C).
Finally, in Fig. 6D we demonstrate that also the insulin-
elicited increase in nuclear PI-PLC-L1 activity was almost
completely blocked by preincubation with PD98059.
4. Discussion
We have found that insulin stimulates the nuclear poly-
phosphoinositide cycle in NIH 3T3 cells, as demonstrated
by DAG mass measurement and PI-PLC activity assays.
The results we have obtained are superimposable on our
own ¢ndings obtained with IGF-I-treated Swiss 3T3 cells
[9,11]. As previously reported by Divecha et al. [4], insulin-
induced changes in nuclear inositol metabolism were seen only
in nuclei stripped of their envelopes by detergent treatment.
This is highly suggestive of events taking place in the nuclear
interior and not at the periphery of the organelle.
Moreover, we have demonstrated that, in response to insu-
lin, only nuclear PI-PLC-L1 was activated, even though the
nucleus of NIH 3T3 cells also contains the L2, L3, and L4
isozymes of PI-PLC. It should be remembered that our pre-
vious results have indicated that, all together, PI-PLC-L2, -L3,
and -L4 represent less than 50% of the L family of PI-PLC in
membrane-deprived nuclei of NIH 3T3 cells and that the ac-
tivity due to these isoforms is about 35% of the total nuclear
PI-PLC activity [16]. In our opinion, the fact that almost no
activity was immunoprecipitated by the antibodies to these
three isoforms indicates that they are not active in the nucleus
upon insulin stimulation. The slight inhibition of the basal
activity ascribed to the L2, L3, and L4 isozymes after immu-
noprecipitation of the nuclear lysates is compatible with the
amount of these isoforms, also taking into account that the
antibodies did not completely immunodeplete the lysates (data
not shown).
Upon treatment with insulin, MAP kinase translocated to
the nucleus, and PI-PLC-L1 was phosphorylated on serine
residues, as indicated by the use of both the lysates from in
vivo [32P]orthophosphate-labeled cells and a monoclonal anti-
body raised against phosphoserine residues. In this context, it
should be recalled that at amino acids 980^983 the phospho-
lipase displays a typical MAP kinase consensus sequence, that
is Pro-Ser-Ser-Pro [21,22]. It is of great interest that such a
sequence does not exist in other isoforms of the L family of
PI-PLC, and this is in agreement with the fact that insulin
activates only nuclear PI-PLC-L1. MAP kinase translocation
to the nucleus as well as PI-PLC-L1 phosphorylation and
activation were markedly reduced by the speci¢c MEK phar-
macological inhibitor PD98059. Taken together, these ¢ndings
strongly suggest that nuclear PI-PLC-L1 is activated upon its
phosphorylation by MAP kinase. These results extend and
support the data of a previous investigation, in which phos-
phorylation of nuclear PI-PLC-L1 was detected in cells that
had been radiolabeled in vivo with [32P]orthophosphate. If
MAP kinase translocation to the nucleus was blocked by cy-
toskeleton depolymerization, no phosphorylation and activa-
tion of PI-PLC-L1 were detectable [14]. We would like to
emphasize that our data show that particularly the b subtype
of PI-PLC-L1 was hyperphosphorylated upon treatment of
quiescent NIH 3T3 cells with insulin. It is now accepted
that this subtype of PI-PLC-L1 is more abundantly expressed
in the nucleus, while subtype a predominates in the cytoplasm
[23]. These results appear intriguing, because so far serine
phosphorylation of PLC-L isozymes by either protein kinase
A or protein kinase C has been regarded as a mechanism to
inhibit their GTP binding protein-dependent activation [24^
26]. However, in these cases the serine residue involved is
1105. Moreover, our results establish yet another di¡erence
between the nuclear inositide cycle and the same cycle which
operates at the plasma membrane level : membrane-associated
PI-PLC-L isoforms are stimulated through interaction with
Fig. 6. Insulin (Ins) induces serine phosphorylation of nuclear PI-
PLC-L1. A: Western blotting analysis showing immunoprecipitated
nuclear PI-PLC-L1 from control and insulin-treated samples. B: The
blot from A was stripped and then reprobed with a monoclonal
antibody to phosphoserine. C: Autoradiogram of immunoprecipi-
tated nuclear PI-PLC-L1 from [32P]orthophosphate-labeled control
and insulin-treated cells. D: PD98059 blocks the insulin-evoked rise
in nuclear PI-PLC activity. In D, results represent the mean þ S.D.
of triplicate determinations.
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the GKq class of heterotrimeric GTP binding proteins as well
as by LQ subunits [27]. In contrast, either GTPQS or AlF4
failed to stimulate PI-PLC-L1 activity in Swiss 3T3 cell iso-
lated nuclei, thus ruling out the hypothesis that a GTP bind-
ing protein could be responsible for the activation of PI-PLC-
L1 in this organelle [28].
In conclusion, we believe we have identi¢ed a novel mech-
anism which controls the activity of nuclear PI-PLC-L1, and
we have also begun to clarify how a signal, generated at the
plasma membrane, can reach the nucleus to stimulate the
residing inositol lipid cycle. Future investigations will un-
doubtedly clarify how other steps of this cycle are regulated
at the nuclear level.
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